HOME >> MEDICINE >> NEWS
Treatment has demonstrated improvement in physical function and kept joint damage from progressing

THOUSAND OAKS, Calif. and COLLEGEVILLE, Pa., November 13, 2005 Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced data from a long-term blinded study of anti-TNF agent in patients with rheumatoid arthritis (RA) demonstrated that more than three quarters of patients treated with Enbrel (etanercept) plus methotrexate combination therapy experienced no progression of joint damage at three years. These new results from the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study will be presented at the American College of Rheumatology's (ACR) Annual Scientific Meeting in San Diego, California.

"Rheumatoid arthritis is a chronic condition requiring long-term treatment. It is critical to provide patients with treatment options that not only reduce the signs and symptoms of the disease, but also inhibit the progression of joint damage," said Dsire van der Heijde, M.D., professor of rheumatology, University of Maastricht in the Netherlands. "The TEMPO results reinforce the benefits of ENBREL and methotrexate combination therapy and underscore the importance of effective treatment."

At three years, the majority of patients taking ENBREL and methotrexate combination therapy had no progression of joint damage. These results were significantly better than those achieved in ENBREL monotherapy and methotrexate monotherapy-treated patients. Patients receiving ENBREL monotherapy also had significantly better results than patients receiving methotrexate monotherapy. Total Sharp Score was calculated by assessing changes in joint space narrowing and bone erosion as captured by radiographic imaging.

Further, additional data presented at ACR showed that improvement in physical function was higher for the ENBREL combination group than for either therapy alone. Patients treated with ENBREL combination therapy experienced a 56 percent mean improvement in Health Assessment
'"/>

Contact: Christine Cassiano, Amgen
805-447-4587
Porter Novelli
15-Nov-2005


Page: 1 2

Related medicine news :

1. Treatment for early prostate cancer associated with type of specialist seen
2. Treatment outcomes of patients with HIV and tuberculosis
3. Treatment of kidney condition requires an individualized approach
4. Treatment of in-hospital cardiac patients is focus of Jefferson University presentations
5. Treatment for homeless youth pays off in long run, study finds
6. Treatment discovered for deadly childhood disease
7. Treatment developed for patients with medically unexplained symptoms
8. Treatment drug may cause jawbone to die
9. Treatment for anorexia nervosa appears to have improved outcome
10. Treatment reduces gastric ulcers in at-risk patients using long-term NSAIDS
11. North Central Cancer Treatment Group finding ways to make treatment easier

Post Your Comments:
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... One of ... interviews to discuss his new book, The Pain Antidote , which provides strategies ... of Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction ...
(Date:8/4/2015)... ... 04, 2015 , ... 24/7 Care At Home , a provider of ... today announced that the U.S. Department of Veteran’s Affairs (VA) has awarded its agency ... is well on the path to meeting the aspirational goals the VA promotes each ...
(Date:8/4/2015)... ... 04, 2015 , ... Increasingly, patients are researching online to ... In an effort to share more and better information with these savvy and ... share patient satisfaction ratings and comments about its doctors and advanced practice providers. ...
(Date:8/4/2015)... ... August 04, 2015 , ... SanusEO, the healthcare industry ... its executive leadership team as Senior Vice President of Sales and Marketing. Mr. ... expanding global markets with a special emphasis on the healthcare industry. , Today, ...
(Date:8/4/2015)... NJ (PRWEB) , ... August 04, 2015 , ... Montclair ... Arts and Health, the first of its kind in New Jersey, which starting this ... of the Arts and Graduate School partnered with Atlantic Health System, one of the ...
Breaking Medicine News(10 mins):Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 2Health News:Atlantic Health System & Montclair State University Launch Graduate Program in Arts & Health 3
(Date:8/4/2015)... Young Innovations ("Young"), a leading global ... the acquisition of the professional dental contract manufacturing ... MPL PDCMD manufactures fluoride varnish, prophy paste and ... procedures. "This acquisition marks the ... high-growth segments," said Dave Sproat , CEO ...
(Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... second quarter and six months ended June 30, 2015. ... in ITP are progressing and we continue to expect ... Rodriguez , president and chief executive officer of Rigel. ... other clinical programs, including evaluating fostamatinib for new treatment ...
(Date:8/4/2015)... SEATTLE , Aug. 4, 2015  Dr. ... Institute states the potential FDA approval of flibanserin, ... sets women and the treatment of decreased female ... women has many root causes and addressing libido ... is dangerous. ...
Breaking Medicine Technology:Young Innovations Announces Acquisition of Medical Products Laboratories' Professional Dental Contract Manufacturing Division 2Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
Cached News: